This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The goals of this study are to: (1) compare in a randomized, blinded, prospective fashion the metabolic and clinical impact of routine intraoperative N2O exposure (vs. an anesthetic regimen identical except that N2O is omitted) on elderly patients; (2) examine clinical, demographic, biochemical and genetic features that may distinguish such postoperative changes from those patients without pre-existing cobalamin deficiency and in patients receiving anesthesia without N2O, or that may influence or predict the risk or expression in individual patients; (3) characterize the details of homocysteine and methionine metabolism in early cobalamin deficiency by measuring plasma levels of a broad range of metabolites, study the changes after exposure to N2O and after recovery compared with control subjects, and correlate the metabolic patterns with clinical outcomes as well as with relevant genetic polymorphisms affecting 3 relevant enzymes; and (4) examine the genetic polymorphisms for association with subclinical cobalamin deficiency and with increased (or decreased) susceptability to the metabolic and clinical effects of N2O exposure, in addition to the above mentioned comparison with metabolite levels.

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
General Clinical Research Centers Program (M01)
Project #
5M01RR000047-46
Application #
7378391
Study Section
National Center for Research Resources Initial Review Group (RIRG)
Project Start
2006-04-01
Project End
2007-03-31
Budget Start
2006-04-01
Budget End
2007-03-31
Support Year
46
Fiscal Year
2006
Total Cost
$11,344
Indirect Cost
Name
Weill Medical College of Cornell University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
060217502
City
New York
State
NY
Country
United States
Zip Code
10065
de Simone, Giovanni; Wang, Wenyu; Best, Lyle G et al. (2017) Target organ damage and incident type 2 diabetes mellitus: the Strong Heart Study. Cardiovasc Diabetol 16:64
Gerber, Linda M; Sievert, Lynnette L; Schwartz, Joseph E (2017) Hot flashes and midlife symptoms in relation to levels of salivary cortisol. Maturitas 96:26-32
De Marco, Marina; Gerdts, Eva; Mancusi, Costantino et al. (2017) Influence of Left Ventricular Stroke Volume on Incident Heart Failure in a Population With Preserved Ejection Fraction (from the Strong Heart Study). Am J Cardiol 119:1047-1052
Schachterle, William; Badwe, Chaitanya R; Palikuqi, Brisa et al. (2017) Sox17 drives functional engraftment of endothelium converted from non-vascular cells. Nat Commun 8:13963
Haring, Bernhard; Wang, Wenyu; Fretts, Amanda et al. (2017) Red meat consumption and cardiovascular target organ damage (from the Strong Heart Study). J Hypertens 35:1794-1800
Beheshtian, Azadeh; Shitole, Sanyog G; Segal, Alan Z et al. (2016) Lipoprotein (a) level, apolipoprotein (a) size, and risk of unexplained ischemic stroke in young and middle-aged adults. Atherosclerosis 253:47-53
Leung, Vivien; Chiu, Ya-Lin; Kotler, Donald P et al. (2016) Effect of Recombinant Human Growth Hormone and Rosiglitazone for HIV-Associated Abdominal Fat Accumulation on Adiponectin and other Markers of Inflammation. HIV Clin Trials 17:55-62
Bhatia, Rajeev; Lesser, Daniel J; Oliveira, Flavia G S A et al. (2015) Body Fat Composition: A Predictive Factor for Sleep Related Breathing Disorder in Obese Children. J Clin Sleep Med 11:1039-45
de Simone, Giovanni; Roman, Mary J; De Marco, Marina et al. (2015) Hemodynamic Correlates of Abnormal Aortic Root Dimension in an Adult Population: The Strong Heart Study. J Am Heart Assoc 4:e002309
Ocean, Allyson J; Christos, Paul; Sparano, Joseph A et al. (2014) Phase II trial of bortezomib alone or in combination with irinotecan in patients with adenocarcinoma of the gastroesophageal junction or stomach. Invest New Drugs 32:542-8

Showing the most recent 10 out of 370 publications